Femoston as a hormone replacement therapy for ovarian failure

Abstract

The article presents the results of a number of hemostasis parameters (coagulation, vascular and thrombocytic) and lipoprotein spectra, including apo A-1 and apo B₁₀₀ apoproteins against the background of hormone replacement treatment with Femostone (Solvay, Germany). The results were compared taking into account menstrual cycle phases in perimenopausal patients (with a preserved cycle) and conditional estrogenic, progestagenic phases of Femostone administration. The advantages of the progestagen didrogesterone included in the drug in its effect on the lipid spectrum, apoproteins and some parameters of vascular thrombocyte hemostasis are shown.

Keywords

hemostasis / femostone / hormone replacement therapy / lipid spectrum / apoproteins / perimenopause

References

[1] Репина М.А. Роль ЗГТ в коррекции расстройств, связанных с постменопаузой. Вкн.: Актуальные вопросы терапии и реабилитации больных пожилого возраста. СПб., 1996, 43-44.

[2] Репина М.А. Перспективы помощи женщине в периоде пери- и постменопаузы. Aqua Vitae, 1997, №1, 30-33.

[3] Шитикова А.С., Каргин В.Д., Белязо О.Е. и др. Морфологическая оценка повышенной внутрисосудистой активации тромбоцитов. Методические рекомендации. 1996. С.-Петербург.

[4] Finucane F., Madans I., Bush T. et al. Decreased risk of stroke among postmenopausal hormone users. Arch. Intern. Med., 1993, vol. 153, 73-79.

[5] Folsom A., Wu K., Davis C. et al. Population correlates of plasma fibrinogen and factor VII putative cardiovascular risk factors. Atherosclerosis, 1991, vol. 91, 191- 205.

[6] Haarbo J., Hansen B., Christiansen C. Hormone replacement therapy prevents coronary artery disease in ovariectomized rabbits. АРМ IS, 1991, vol. 99, 721-727.

[7] Kharitonov S., Logan-Sinclar R., Busset C., Shinebourne E. Peak expiratory nitric oxide differences in men and women. Br. Heart J., 1994, vol. 72, 243-245.

[8] Meade T., ImersonJ., Hames A. et al. Menopausal status and haemostatic variables. Lancet, 1983, vol. 71, 23-24.

[9] Nabulsi A., Folsom A., White A. et al. Association of hormone replacement therapy with varies cardiovascular risk factors in postmenopausal women. New Engl. J. Med., 1993, vol. 15, 1069-1075.

[10] Polderman K., Stehouwer C., Van Kamp G. et al. Influence of sex hormones on plasma endothelin levels. Ann. Intern. Med., 1993, vol. 118, 429-432.

[11] Rosano G., Sarrel P., Poole-Wilson P. et al. Beneficial effects of oestrogen in postmenopausal women. Lancet, 1993, vol. 342, 133- 135.

[12] Scarabin P., Bonithon-Kopp C., Bara L. et al. Factor VII activation and menopausal status. Thromb. Res., 1990, vol. 57, 227-234.

RIGHTS & PERMISSIONS

Eсо-Vector